Company Information
Company Profile
Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Latest Presentations
September 2024 Corporate Presentation
View This Presentation
Contact Information
Investor Relations
Avalo Therapeutics
ir@avalotx.com
ICR Westwicke
Chris Brinzey
Managing Director
T: 339-970-2843
chris.brinzey@westwicke.com